Next Article in Journal
Tetrandrine, a Compound Common in Chinese Traditional Medicine, Preferentially Kills Breast Cancer Tumor Initiating Cells (TICs) In Vitro
Next Article in Special Issue
Different Aspects of Self-Reported Quality of Life in 450 German Melanoma Survivors
Previous Article in Journal / Special Issue
Targeted Therapy for Biliary Tract Cancer
Open AccessReview

Targeted Therapy in Nonmelanoma Skin Cancers

Department of Dermatology, University of Rome “Tor Vergata”, Via Montpellier 1, 00199, Rome, Italy
Author to whom correspondence should be addressed.
Cancers 2011, 3(2), 2255-2273;
Received: 11 March 2011 / Revised: 11 April 2011 / Accepted: 26 April 2011 / Published: 3 May 2011
(This article belongs to the Special Issue Cancer Diagnosis and Targeted Therapy)
Nonmelanoma skin cancer (NMSC) is the most prevalent cancer in light-skinned populations, and includes mainly Basal Cell Carcinomas (BCC), representing around 75% of NMSC and Squamous Cell Carcinomas (SCC). The incidence of these tumors is continuously growing. It was found that the overall number of procedures for NMSC in US rose by 76%, from 1,158,298 in 1992 to 2,048,517 in 2006. Although mortality from NMSC tends to be very low, clearly the morbidity related to these skin cancers is very high. Treatment options for NMSC include both surgical and nonsurgical interventions. Surgery was considered the gold standard therapy, however, advancements in the knowledge of pathogenic mechanisms of NMSCs led to the identification of key targets for drug intervention and to the consequent development of several targeted therapies. These represent the future in treatment of these common forms of cancer ensuring a high cure rate, preservation of the maximal amount of normal surrounding tissue and optimal cosmetic outcome. Here, we will review recent advancements in NMSC targeted therapies focusing on BCC and SCC. View Full-Text
Keywords: basal cell carcinoma (BCC); squamous cell carcinoma (SCC); EGFR; SMO inhibitor; COX2 basal cell carcinoma (BCC); squamous cell carcinoma (SCC); EGFR; SMO inhibitor; COX2
MDPI and ACS Style

Spallone, G.; Botti, E.; Costanzo, A. Targeted Therapy in Nonmelanoma Skin Cancers. Cancers 2011, 3, 2255-2273.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop